CollPlant Biotechnologies Ltd (CLGN) Form 6-K — Sep 18, 2026
CollPlant Biotechnologies furnished a 6-K on September 18, 2026 attaching an updated corporate presentation used for its September 17 LightSolver investor webinar, underscoring the Israeli company's repositioning from regenerative-medicine biotech into an optical computing platform built around its LightSolver acquisition. The transaction structure ties future ownership to execution: closing shares plus pre-funded warrants, $5 million in funding to LightSolver at closing, and three additional warrant tranches tied to specified technology and commercial milestones, while CollPlant continues to evaluate strategic alternatives for its existing biotech assets.
Key figures
- Warrant tranches
- 3 milestone-based tranches (Milestone 1, 2, 3)
- Lpu power consumption
- < 1 KW
- Claimed speedup vs gpu
- up to 10,000x (emulation/projection-based)
- Lpu variables per core
- up to 1M
- Sam pde workloads 2034
- $53B
- Lightsolver founding year
- 2020
- Projected hpc market 2034
- $89B (Hyperion Research, 2024)
- Commercial availability target
- 2028
- Boeing corrosion modeling speedup
- up to 100x
- Funding to lightsolver at closing
- $5M
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.